- Home
- EQS vs NERV Comparison
EQS vs NERV Comparison
Compare EQS & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- NERV
- Stock Information
- Founded
- EQS 1991
- NERV 2007
- Country
- EQS United States
- NERV United States
- Employees
- EQS N/A
- NERV N/A
- Industry
- EQS Finance Companies
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- NERV Health Care
- Exchange
- EQS Nasdaq
- NERV Nasdaq
- Market Cap
- EQS 13.9M
- NERV 12.6M
- IPO Year
- EQS N/A
- NERV 2014
- Fundamental
- Price
- EQS $1.38
- NERV $1.77
- Analyst Decision
- EQS
- NERV Hold
- Analyst Count
- EQS 0
- NERV 1
- Target Price
- EQS N/A
- NERV $5.00
- AVG Volume (30 Days)
- EQS 13.5K
- NERV 12.2K
- Earning Date
- EQS 01-01-0001
- NERV 08-05-2025
- Dividend Yield
- EQS N/A
- NERV N/A
- EPS Growth
- EQS N/A
- NERV N/A
- EPS
- EQS N/A
- NERV 0.83
- Revenue
- EQS $1,329,000.00
- NERV N/A
- Revenue This Year
- EQS N/A
- NERV N/A
- Revenue Next Year
- EQS N/A
- NERV N/A
- P/E Ratio
- EQS N/A
- NERV $2.18
- Revenue Growth
- EQS 152.66
- NERV N/A
- 52 Week Low
- EQS $0.74
- NERV $1.15
- 52 Week High
- EQS $1.52
- NERV $3.50
- Technical
- Relative Strength Index (RSI)
- EQS 67.89
- NERV 57.10
- Support Level
- EQS $1.30
- NERV $1.62
- Resistance Level
- EQS $1.39
- NERV $1.83
- Average True Range (ATR)
- EQS 0.05
- NERV 0.09
- MACD
- EQS -0.00
- NERV -0.00
- Stochastic Oscillator
- EQS 94.74
- NERV 64.29
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.